Ginkgo Bioworks in RNA-Discovery Collaboration With Pfizer
By Chris Wack
Ginkgo Bioworks has entered into a collaboration with Pfizer focused on the discovery of RNA-based drug candidates.
In the collaboration, Pfizer will use Ginkgo's proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas.
Ginkgo will receive an upfront payment and is eligible to receive research fees and development and commercial milestone payments, up to $331 million across three programs. Ginkgo is entitled to potential further downstream value in the form of royalties on sales.
Shares of Ginkgo gained 15% to $1.73 in pre-market trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 27, 2023 07:37 ET (11:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk
United States